Safety and Tolerability Study of Acoziborole in g-HAT Seropositive Subjects (OXA004)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05256017 |
|
Recruitment Status :
Recruiting
First Posted : February 25, 2022
Last Update Posted : September 28, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Acoziborole as an oral, single-dose treatment was studied in an open-label pivotal Phase II/III trial (DNDi-OXA-02-HAT) in DRC and Guinea. The safety and efficacy results on g-HAT confirmed cases (all disease stages) from the pivotal study provided data, that allows to envision the treatment of confirmed g-HAT cases but there is still a gap in the management of g-HAT seropositive non-parasitologically confirmed individuals. Indeed, the standard g-HAT case definition implies the demonstration of the parasite in any body fluid via microscopy. However, there are factors such as low parasitaemia and the complexity and low sensitivity of parasitological methods that make such demonstration difficult. It has been demonstrated that a variable proportion (mainly depending on the prevalence) of such g-HAT "sero-suspects" are confirmed cases and, therefore, remaining as potential reservoirs of the parasite and a source of new infections hindering the efforts to eliminate the disease.
The present clinical trial intends to expand the safety data of acoziborole and complement the safety profile obtained from the pivotal trial by assessing the safety and tolerability of a single dose of acoziborole compared with placebo in seropositive individuals who are not confirmed parasitologically.
In addition to this study, an exploratory sub-study named 'TrypSkin' is planned to assess the presence of extravascular dermal T.b. gambiense in the population enrolled.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Trypanosomiasis, African Trypanosoma Brucei Gambiense; Infection Sleeping Sickness | Drug: Acoziborole Drug: Placebo | Phase 2 Phase 3 |
HAT is a neglected tropical disease, transmitted by the bite of a tsetse fly, affecting sub-Saharan African countries. Without prompt diagnosis and treatment, it is usually fatal, as the parasites responsible for HAT (Trypanosoma brucei gambiense [T.b. gambiense or g-HAT] or Trypanosoma brucei rhodesiense [T.b. rhodesiense]) invade the central nervous system (late stage of the disease) causing neurological changes which include among other symptoms sleep disorder, aggression, sensory disturbances, psychosis, seizures, coma, and ultimately death. Eight and a half million people, living mainly in rural parts of East, West, and Central Africa, are situated in areas where g-HAT is still considered a public health problem. Whereas, fifty-three million people are estimated to be at risk of infection on the African continent.
Few therapeutic options are currently available to treat g-HAT at either the haemolymphatic (early) stage or meningoencephalitic (late) stage. When early stage g-HAT is diagnosed, patients can be treated in their villages with intramuscular injections of pentamidine for 7 days. In patients with late-stage g-HAT, nifurtimox-eflornithine combination therapy (NECT), a combination of oral nifurtimox for 10 days plus eflornithine, two 2-hour intravenous (IV) infusions daily for 7 days, was found to provide similar cure rates to the standard regimen with eflornithine for 14 days, but with obvious practical advantages, including ease of administration and a shorter duration of treatment. In December 2018, Fexinidazole was approved for the treatment of g-HAT in the Democratic Republic of Congo (DRC), which is an effective 10-day oral treatment, able to cure early and late stage patients, although an increased risk of relapse on very advanced patients keeps NECT as first line treatment for patients showing more than 100 white blood cells (WBC)/µL of cerebrospinal fluid on diagnosis.
Whilst the delivery of fexinidazole has improved the management of g-HAT cases and facilitates the integration of HAT treatment into the general health system, Acoziborole (studied in an open-label pivotal Phase II/III trial) as an oral, single-dose treatment envisioned for all stages of g-HAT is expected to improve further the management of g-HAT cases. However, there is still a gap in the management of g-HAT seropositive non-parasitologically confirmed individuals. Indeed, the standard g-HAT case definition implies the demonstration of the parasite in any body fluid via microscopy. But, there are factors such as low parasitaemia and the complexity and low sensitivity of parasitological methods that make such demonstration difficult. It has been demonstrated that a variable proportion (mainly depending on the prevalence) of such g-HAT "sero-suspects" are confirmed cases and, therefore, remaining as potential reservoirs of the parasite and a source of new infections hindering the efforts to eliminate the disease.
The present clinical trial intends to expand the safety data of acoziborole and complement the safety profile obtained from the pivotal trial by assessing the safety and tolerability of a single dose of acoziborole compared with placebo in seropositive individuals who are not confirmed parasitologically.
In addition to this study, an exploratory sub-study named 'TrypSkin' is planned to assess the presence of extravascular dermal T.b. gambiense in the population enrolled. Indeed, in an observational cohort study conducted in Guinea, the presence of extravascular dermal trypanosomes has been observed in individuals presenting with CATT positive results in plasma dilution ≥1:4 but not confirmed by parasitological examination of blood and lymph. If these dermal trypanosomes correspond to T.b. gambiense subspecies and are able to infect vectors, these individuals could act as reservoirs for the transmission of g-HAT, hampering the elimination goal.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 1200 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | 2 arms (acoziborole and placebo, ratio 3:1); 5 days post drug administration of hospitalization; follow-up visits at Month 1 and Month 4 (End of Study Visit) |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | Safety and Tolerability Study of Acoziborole in g-HAT Seropositive Non-parasitologically Confirmed Subjects: a Multicentre Randomised Double-blind Placebo-controlled Study |
| Actual Study Start Date : | December 30, 2021 |
| Estimated Primary Completion Date : | May 1, 2023 |
| Estimated Study Completion Date : | May 1, 2023 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Acoziborole
Single dose administration of 3 tablets of 320 mg
|
Drug: Acoziborole
Acoziborole tablets |
|
Placebo Comparator: Placebo
Single dose administration of 3 tablets of 320 mg
|
Drug: Placebo
matching placebo of acoziborole tablets |
- Occurrence of treatment-emergent adverse events (TEAEs) [ Time Frame: From Investigational Product administration to 4 months follow up visit (End of Study) ]Occurrence of any Treatment Emergent Adverse Event from investigational product administration to 4 month follow-up visit
- Occurrence of adverse events (AEs) [ Time Frame: From Inform Consent signature to 4 months follow up visit (End of Study) ]Occurrence of any Adverse Event from Inform Consent signature to 4 month follow-up visit
- Change from baseline in biochemistry parameter: Alanine Aminotransferase [ Time Frame: From Inform Consent signature to 4 months follow up visit (End of Study) ]Changes from baseline at D5, M1 and M4 will be will be presented by treatment group and summarized using mean, standard deviation, median, interquartile range (Q1-Q2) and range (minimum - maximum). Changes from baseline will also be presented as shift table expressed by % of subjects with low, normal or high value for each parameter and each timepoint.
- Change from baseline in biochemistry parameter: Albumin [ Time Frame: From Inform Consent signature to 4 months follow up visit (End of Study) ]Changes from baseline at D5, M1 and M4 will be will be presented by treatment group and summarized using mean, standard deviation, median, interquartile range (Q1-Q2) and range (minimum - maximum). Changes from baseline will also be presented as shift table expressed by % of subjects with low, normal or high value for each parameter and each timepoint.
- Change from baseline in biochemistry parameter: Alkaline Phosphatase [ Time Frame: From Inform Consent signature to 4 months follow up visit (End of Study) ]Changes from baseline at D5, M1 and M4 will be will be presented by treatment group and summarized using mean, standard deviation, median, interquartile range (Q1-Q2) and range (minimum - maximum). Changes from baseline will also be presented as shift table expressed by % of subjects with low, normal or high value for each parameter and each timepoint.
- Change from baseline in biochemistry parameter: Aspartate Aminotransferase [ Time Frame: From Inform Consent signature to 4 months follow up visit (End of Study) ]Changes from baseline at D5, M1 and M4 will be will be presented by treatment group and summarized using mean, standard deviation, median, interquartile range (Q1-Q2) and range (minimum - maximum). Changes from baseline will also be presented as shift table expressed by % of subjects with low, normal or high value for each parameter and each timepoint.
- Change from baseline in biochemistry parameter: Calcium [ Time Frame: From Inform Consent signature to 4 months follow up visit (End of Study) ]Changes from baseline at D5, M1 and M4 will be will be presented by treatment group and summarized using mean, standard deviation, median, interquartile range (Q1-Q2) and range (minimum - maximum). Changes from baseline will also be presented as shift table expressed by % of subjects with low, normal or high value for each parameter and each timepoint.
- Change from baseline in biochemistry parameter: Chloride [ Time Frame: From Inform Consent signature to 4 months follow up visit (End of Study) ]Changes from baseline at D5, M1 and M4 will be will be presented by treatment group and summarized using mean, standard deviation, median, interquartile range (Q1-Q2) and range (minimum - maximum). Changes from baseline will also be presented as shift table expressed by % of subjects with low, normal or high value for each parameter and each timepoint.
- Change from baseline in biochemistry parameter: Creatinine [ Time Frame: From Inform Consent signature to 4 months follow up visit (End of Study) ]Changes from baseline at D5, M1 and M4 will be will be presented by treatment group and summarized using mean, standard deviation, median, interquartile range (Q1-Q2) and range (minimum - maximum). Changes from baseline will also be presented as shift table expressed by % of subjects with low, normal or high value for each parameter and each timepoint.
- Change from baseline in biochemistry parameter: Glucose [ Time Frame: From Inform Consent signature to 4 months follow up visit (End of Study) ]Changes from baseline at D5, M1 and M4 will be will be presented by treatment group and summarized using mean, standard deviation, median, interquartile range (Q1-Q2) and range (minimum - maximum). Changes from baseline will also be presented as shift table expressed by % of subjects with low, normal or high value for each parameter and each timepoint.
- Change from baseline in biochemistry parameter: Potassium [ Time Frame: From Inform Consent signature to 4 months follow up visit (End of Study) ]Changes from baseline at D5, M1 and M4 will be will be presented by treatment group and summarized using mean, standard deviation, median, interquartile range (Q1-Q2) and range (minimum - maximum). Changes from baseline will also be presented as shift table expressed by % of subjects with low, normal or high value for each parameter and each timepoint.
- Change from baseline in biochemistry parameter: Sodium [ Time Frame: From Inform Consent signature to 4 months follow up visit (End of Study) ]Changes from baseline at D5, M1 and M4 will be will be presented by treatment group and summarized using mean, standard deviation, median, interquartile range (Q1-Q2) and range (minimum - maximum). Changes from baseline will also be presented as shift table expressed by % of subjects with low, normal or high value for each parameter and each timepoint.
- Change from baseline in biochemistry parameter: Total Bilirubin [ Time Frame: From Inform Consent signature to 4 months follow up visit (End of Study) ]Changes from baseline at D5, M1 and M4 will be will be presented by treatment group and summarized using mean, standard deviation, median, interquartile range (Q1-Q2) and range (minimum - maximum). Changes from baseline will also be presented as shift table expressed by % of subjects with low, normal or high value for each parameter and each timepoint.
- Change from baseline in biochemistry parameter: Total Carbon Dioxide [ Time Frame: From Inform Consent signature to 4 months follow up visit (End of Study) ]Changes from baseline at D5, M1 and M4 will be will be presented by treatment group and summarized using mean, standard deviation, median, interquartile range (Q1-Q2) and range (minimum - maximum). Changes from baseline will also be presented as shift table expressed by % of subjects with low, normal or high value for each parameter and each timepoint.
- Change from baseline in biochemistry parameter: Total Protein [ Time Frame: From Inform Consent signature to 4 months follow up visit (End of Study) ]Changes from baseline at D5, M1 and M4 will be will be presented by treatment group and summarized using mean, standard deviation, median, interquartile range (Q1-Q2) and range (minimum - maximum). Changes from baseline will also be presented as shift table expressed by % of subjects with low, normal or high value for each parameter and each timepoint.
- Change from baseline in biochemistry parameter: Blood Urea Nitrogen [ Time Frame: From Inform Consent signature to 4 months follow up visit (End of Study) ]Changes from baseline at D5, M1 and M4 will be will be presented by treatment group and summarized using mean, standard deviation, median, interquartile range (Q1-Q2) and range (minimum - maximum). Changes from baseline will also be presented as shift table expressed by % of subjects with low, normal or high value for each parameter and each timepoint.
- Change from baseline in hematology parameter: hemoglobin [ Time Frame: From Inform Consent signature to 4 months follow up visit (End of Study) ]Changes from baseline at D5, M1 and M4 will be will be presented by treatment group and summarized using mean, standard deviation, median, interquartile range (Q1-Q2) and range (minimum - maximum). Changes from baseline will also be presented as shift table expressed by % of subjects with low, normal or high value for each parameter and each timepoint.
- Change from baseline in hematology parameter: Platelets [ Time Frame: From Inform Consent signature to 4 months follow up visit (End of Study) ]Changes from baseline at D5, M1 and M4 will be will be presented by treatment group and summarized using mean, standard deviation, median, interquartile range (Q1-Q2) and range (minimum - maximum). Changes from baseline will also be presented as shift table expressed by % of subjects with low, normal or high value for each parameter and each timepoint.
- Change from baseline in hematology parameter: white blood cells [ Time Frame: From Inform Consent signature to 4 months follow up visit (End of Study) ]Changes from baseline at D5, M1 and M4 will be will be presented by treatment group and summarized using mean, standard deviation, median, interquartile range (Q1-Q2) and range (minimum - maximum). Changes from baseline will also be presented as shift table expressed by % of subjects with low, normal or high value for each parameter and each timepoint.
- Change from baseline in ECG (Electrocardiogram) parameter: heart rate (HR) [ Time Frame: From Inform Consent signature to Day 5 (end of Hospitalization) ]change from baseline (Δ) at D5 will be summarized by treatment group and Placebo -corrected change from baseline (ΔΔ) will be calculated using an analysis of covariance model adjusting for sex and age.
- Change from baseline in ECG (Electrocardiogram) parameter: RR interval [ Time Frame: From Inform Consent signature to Day 5 (end of Hospitalization) ]change from baseline (Δ) at D5 will be summarized by treatment group and Placebo -corrected change from baseline (ΔΔ) will be calculated using an analysis of covariance model adjusting for sex and age.
- Change from baseline in ECG (Electrocardiogram) parameter: PR interval [ Time Frame: From Inform Consent signature to Day 5 (end of Hospitalization) ]change from baseline (Δ) at D5 will be summarized by treatment group and Placebo -corrected change from baseline (ΔΔ) will be calculated using an analysis of covariance model adjusting for sex and age.
- Change from baseline in ECG (Electrocardiogram) parameter: QRS interval [ Time Frame: From Inform Consent signature to Day 5 (end of Hospitalization) ]change from baseline (Δ) at D5 will be summarized by treatment group and Placebo -corrected change from baseline (ΔΔ) will be calculated using an analysis of covariance model adjusting for sex and age.
- Change from baseline in ECG (Electrocardiogram) parameter: QT interval [ Time Frame: From Inform Consent signature to Day 5 (end of Hospitalization) ]change from baseline (Δ) at D5 will be summarized by treatment group and Placebo -corrected change from baseline (ΔΔ) will be calculated using an analysis of covariance model adjusting for sex and age.
- Change from baseline in ECG (Electrocardiogram) parameter: QTc interval [ Time Frame: From Inform Consent signature to Day 5 (end of Hospitalization) ]change from baseline (Δ) at D5 will be summarized by treatment group and Placebo -corrected change from baseline (ΔΔ) will be calculated using an analysis of covariance model adjusting for sex and age.
- Blood concentration of acoziborole at Day 5 and Month 1 [ Time Frame: Day 5 and 1 month follow-up visit ]Concentration of acoziborole in whole blood at Day 5 and Month 1
- Correlation between ΔQTc measurements and acoziborole concentrations in blood at Day 5 [ Time Frame: Day 5 ]
- Exploratory outcome: occurrence of dermatitis and/or pruritus [ Time Frame: From Inform Consent signature to 4 months follow up visit (End of Study) ]
- Exploratory outcome: occurrence of positive results on blood and skin samples analyzed by Immuno-Histochemistry (IHC), TBR- PCR and/or 18S-PCR [ Time Frame: From Inform Consent signature to 4 months follow up visit (End of Study) ]
- Exploratory outcome: occurrence of positive results on blood and skin samples analyzed by qPCRs, multiplex qRT-PCRs and SHERLOCK (Specific High-sensitivity Enzymatic Reporter unlocking) [ Time Frame: From Inform Consent signature to 4 months follow up visit (End of Study) ]
- Exploratory outcome: descriptive comparisons between groups and timepoints in occurrence of dermatitis, pruritus, positive results in skin and blood samples analyzed by IHC, qPCRs, multiplex qRT-PCRs and SHERLOCK [ Time Frame: From Inform Consent signature to 4 months follow up visit (End of Study) ]
- Exploratory outcome: occurrence comparisons between all diagnostic methods alone or in combination [ Time Frame: From Inform Consent signature to 4 months follow up visit (End of Study) ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 15 Years and older (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Signed the informed consent form
- Male or female
- 15 years of age or older
- CATT test or HAT sero-K-set RDT positive
- Parasitology negative (in blood and/or lymph if lymphadenopathy is present)
- Karnofsky Performance Status above 70
- Able to ingest oral tablets
- Known address and/or contact details provided
- Must be able to comply with the schedule of follow-up visits and other requirements of the study
- Agreement to be hospitalised upon enrolment for at least 5 days (in order to receive in-ward post-treatment observational follow-up through the first 5 days after treatment)
- Agreement to not take part in any other clinical trials during the participation in this study
-
For women of childbearing potential:
- Must agree to have protected sexual relations to avoid becoming pregnant from enrolment up to 3 months after dosing
- Negative urine pregnancy tests
Exclusion Criteria:
- Individuals parasitologically confirmed in blood and/or lymph
- Previously treated for g-HAT
- Severe malnutrition, defined as body mass index (BMI) <16 kg/m2
- Pregnant or breast-feeding women
-
For women of childbearing potential:
- Urine pregnancy test positive
- Do not accept contraceptive protection from enrolment up to 3 months after dosing
- Clinically significant medical condition and/or abnormal laboratory results that could, in the opinion of the Investigator, jeopardise the subject's safety or participation in the study
Additional exclusion criteria for the TrypSkin exploratory sub-study:
- Rejection to participate in the exploratory sub-study in the signed ICF
- Known diabetes
- Known haemophilia
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05256017
| Contact: Antoine TARRAL, Dr. | +41 22 906 92 60 | antoine.tarral@dndi.org | |
| Contact: Adeline PRÊTRE | +41 22 907 77 22 | apretre@dndi.org |
| Congo, The Democratic Republic of the | |
| General Referral Hospital of Bagata | Recruiting |
| Kwilu, Bandundu, Congo, The Democratic Republic of the | |
| Contact: Dr John TAMPWO jtampwo@extern.dndi.org | |
| Contact: Dr Patrick NDUWA pnduwa@extern.dndi.org | |
| Hospital of Dipumba | Recruiting |
| Mbuji-Mayi, Kasai-Oriental, Congo, The Democratic Republic of the | |
| Contact: Médard ILUNGA, Dr. milunga@extern.dndi.org | |
| Contact: Dieudonné MPOYI, Dr. mpoyi@extern.dndi.org | |
| Principal Investigator: Médard ILUNGA, Dr. | |
| Sub-Investigator: Dieudonné MPOYI, Dr. | |
| General Referral Hospital of Idiofa | Recruiting |
| Idiofa, Kwilu, Congo, The Democratic Republic of the | |
| Contact: Dr Toussaint OZANKOM tozankom@extern.dndi.org | |
| Contact: Dr Francis NYOKA francisnioka65@gmail.com | |
| General Referral Hospital of Masi-Manimba | Recruiting |
| Masi-Manimba, Kwilu, Congo, The Democratic Republic of the | |
| Contact: Augustin Augustin, Dr. akukembila@dndi.org | |
| Contact: Félix AKWASO, Dr. fakwaso@extern.dndi.org | |
| Principal Investigator: Augustin Augustin, Dr. | |
| Sub-Investigator: Félix AKWASO, Dr. | |
| General Referral Hospital of Kwamouth | Recruiting |
| Kwamouth, Mai-Ndombe, Congo, The Democratic Republic of the | |
| Contact: Dr Hugue Embana | |
| Contact: Dr Jean Pierre Kokengo | |
| General Hospital of Bandundu | Recruiting |
| Bandundu, Congo, The Democratic Republic of the | |
| Contact: Lionel NGIMBA, Dr. lngimba@extern.dndi.org | |
| Contact: Joseph MAKAYA, Dr. jmakaya@extern.dndi.org | |
| Principal Investigator: Lionel NGIMBA, Dr. | |
| Sub-Investigator: Joseph MAKAYA, Dr. | |
| Guinea | |
| General Referral Hospital of Dubreka | Recruiting |
| Dubréka, Dubreka, Guinea | |
| Contact: Mamadou BAILO DIALLO, Dr. bailodiallo3@yahoo.fr | |
| Contact: Alseny M'MAH SOUMATH, Dr. alsenymmahsoumah15@gmail.com | |
| Principal Investigator: Mamadou BAILO DIALLO, Dr. | |
| Sub-Investigator: Alseny M'MAH SOUMATH, Dr. | |
| Principal Investigator: | Victor Kande Betu Ku Mesu, Dr. | Ministry of Public Health, Hygiene and Prevention, Kinshasa |
| Responsible Party: | Drugs for Neglected Diseases |
| ClinicalTrials.gov Identifier: | NCT05256017 |
| Other Study ID Numbers: |
DNDi-OXA-04-HAT |
| First Posted: | February 25, 2022 Key Record Dates |
| Last Update Posted: | September 28, 2022 |
| Last Verified: | September 2022 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Human African Trypanosomiasis Trypanosoma Brucei Gambiense Sleeping sickness g-HAT g-HAT seropositive individuals |
|
Trypanosomiasis Trypanosomiasis, African Euglenozoa Infections Protozoan Infections |
Parasitic Diseases Infections Vector Borne Diseases |